Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
Shineco (NASDAQ: SISI) has announced two major strategic developments in its biocellular technology business. First, its subsidiary Dong'ao Health secured a $8.7 million technology services contract with Xinke Future Biotechnology for developing microalgae-derived extracellular vesicles technology, with an initial payment of $560,000 already received. The contract runs from August 2025 to December 2026.
Second, Shineco formed a strategic alliance with Singapore's BICC, following a high-level delegation visit. The partnership includes establishing a joint laboratory, implementing technology exchange mechanisms, and integrating BICC's 3,000+ Southeast Asian agents with Dong'ao Health's domestic wellness channels. The collaboration aims to develop stem cell transfusion centers and standardized clinical services.
Shineco (NASDAQ: SISI) ha annunciato due significativi sviluppi strategici nel proprio settore di biocellulare. In primo luogo, la controllata Dong'ao Health ha ottenuto un contratto di servizi tecnologici da 8,7 milioni di dollari con Xinke Future Biotechnology per lo sviluppo della tecnologia delle vescicole extracellulari derivate da microalghe, con un pagamento iniziale di 560.000 dollari già ricevuto. Il contratto ha validità da agosto 2025 a dicembre 2026.
In secondo luogo, Shineco ha stipulato un'alleanza strategica con il BICC di Singapore, in seguito a una visita di una delegazione di alto livello. La partnership prevede l'istituzione di un laboratorio congiunto, l'attuazione di meccanismi di scambio tecnologico e l'integrazione dei più di 3.000 agenti del Sud-Est asiatico appartenenti al BICC con i canali di benessere domestico di Dong'ao Health. L'obiettivo della collaborazione è sviluppare centri di trasfusione di cellule staminali e servizi clinici standardizzati.
Shineco (NASDAQ: SISI) ha anunciado dos desarrollos estratégicos importantes en su negocio de biocelulares. En primer lugar, su filial Dong'ao Health obtuvo un contrato de servicios tecnológicos por 8,7 millones de dólares con Xinke Future Biotechnology para desarrollar la tecnología de vesículas extracelulares derivadas de microalgas, con un pago inicial de 560.000 dólares ya recibido. El contrato va de agosto de 2025 a diciembre de 2026.
En segundo lugar, Shineco formó una alianza estratégica con el BICC de Singapur, tras una visita de una delegación de alto nivel. La asociación incluye establecer un laboratorio conjunto, implementar mecanismos de intercambio tecnológico e integrar a los más de 3.000 agentes del Sudeste Asiático del BICC con los canales de bienestar domésticos de Dong'ao Health. La colaboración tiene como objetivo desarrollar centros de transfusión de células madre y servicios clínicos estandarizados.
Shineco (NASDAQ: SISI)가 생체세포 기술 사업에서 두 가지 주요 전략적 발전을 발표했습니다. 첫째로 자회사 Dong'ao Health가 Xinke Future Biotechnology와 미세조류 유래의 외세포 소포 기술 개발을 위한 870만 달러의 기술 서비스 계약을 체결했으며, 이미 56만 달러의 초기 지급액을 받았습니다. 계약 기간은 2025년 8월부터 2026년 12월까지입니다.
둘째로 Shineco는 고위급 대표단 방문 이후 싱가포르의 BICC와 전략적 동맹을 형성했습니다. 파트너십은 공동 연구소 설립, 기술 교류 메커니즘 구현, 동남아시아 지역의 3,000명 넘는 대리점을 Dong'ao Health의 국내 웰니스 채널과 통합하는 것을 포함합니다. 협력의 목표는 줄기세포 수혈 센터를 개발하고 표준화된 임상 서비스를 제공하는 것입니다.
Shineco (NASDAQ: SISI) a annoncé deux développements stratégiques majeurs dans son secteur biocellulaire. Premièrement, sa filiale Dong'ao Health a obtenu un contrat de services technologiques de 8,7 millions de dollars avec Xinke Future Biotechnology pour développer la technologie des vésicules extracellulaires dérivées des microalgues, avec un paiement initial de 560 000 dollars déjà reçu. Le contrat s’étend d’août 2025 à décembre 2026.
Deuxièmement, Shineco a formé une alliance stratégique avec le BICC de Singapour, à la suite d’une visite d’une délégation de haut niveau. Le partenariat prévoit la création d’un laboratoire commun, la mise en place de mécanismes d’échange technologique et l’intégration des plus de 3 000 agents d’Asie du Sud-Est du BICC avec les canaux de bien-être domestiques de Dong'ao Health. La collaboration vise à développer des centres de transfusion de cellules souches et des services cliniques standardisés.
Shineco (NASDAQ: SISI) hat zwei wesentliche strategische Entwicklungen in seinem biokörpertechnologischen Geschäft bekannt gegeben. Erstens hat die Tochter Dong'ao Health einen Technikdienstleistungsvertrag über 8,7 Mio. USD mit Xinke Future Biotechnology zur Entwicklung mikroalgenabgeleiteter extrazellulärer Vesikeltechnologie erhalten, wobei eine anfängliche Zahlung von 560.000 USD bereits erfolgt ist. Der Vertrag läuft von August 2025 bis Dezember 2026.
Zweitens hat Shineco nach einem Besuch einer hochrangigen Delegation eine strategische Allianz mit dem BICC von Singapur gebildet. Die Partnerschaft umfasst die Einrichtung eines gemeinsamen Labors, die Umsetzung von Mechanismen zum Technologietausch und die Integration der über 3.000 südostasiatischen Vertriebsagenten des BICC mit den heimischen Wellnesskanälen von Dong'ao Health. Ziel der Zusammenarbeit ist die Entwicklung von Stammzell-Transfusionszentren und standardisierten klinischen Diensten.
Shineco (NASDAQ: SISI) أعلنت عن تطورين استراتيجيين رئيسيين في قطاع تكنولوجيا الخلايا الحيوية لديها. أولاً، حصلت شركة Dong'ao Health التابعة لها على عقد خدمات تكنولوجية بقيمة 8.7 ملايين دولار مع Xinke Future Biotechnology لتطوير تقنية الحويصلات خارج الخلية المشتقة من الطحالب الدقيقة، مع استلام دفعة ابتدائية قدرها 560,000 دولار بالفعل. مدة العقد من أغسطس 2025 إلى ديسمبر 2026.
ثانياً، شكلت Shineco تحالفاً استراتيجياً مع BICC في سنغافورة، عقب زيارة وفد رفيع المستوى. تشمل الشراكة إنشاء مختبر مشترك، تنفيذ آليات تبادل تكنولوجي، ودمج أكثر من 3,000 وكيل في جنوب شرق آسيا من BICC مع قنوات العافية المحلية لدى Dong'ao Health. يهدف التعاون إلى تطوير مراكز نقل الدم للخلايا الجذعية وخدمات سريرية موحدة.
Shineco（纳斯达克股票代码：SISI）宣布在其生物细胞技术业务中有两项重大战略发展。首先，其子公司东澳健康与 Xinke Future Biotechnology签署了一份价值 870万美元的技术服务合同，用于开发微藻来源的细胞外囊泡技术，已收到首笔 56万美元 的款项。该合同期限为 2025 年 8 月至 2026 年 12 月。
其次，Shineco 在对方高层代表团访问后与新加坡的 BICC 建立了战略联盟。该伙伴关系包括设立联合实验室、实施技术交流机制，并将 BICC 的 3,000 名以上东南亚代理商 与 Dong'ao Health 的国内健康渠道整合在一起。合作的目标是开发干细胞输注中心并提供标准化的临床服务。
- Secured $8.7 million technology services contract with clear payment milestones
- Initial payment of $560,000 already received
- Strategic partnership with BICC provides access to 3,000+ agents in Southeast Asia
- Development of multiple revenue streams through 'develop once, deploy multiple times' technology model
- Long development timeline extending to December 2026
- Success dependent on achieving R&D milestones for subsequent payments
- Significant investment required in joint laboratory and infrastructure development
Insights
Shineco secures $8.7M biotech contract and Singapore partnership, creating dual revenue streams and expanding international market reach.
This dual announcement represents significant operational momentum for Shineco's iPSC technology commercialization strategy. The
More importantly, the contract's structure reveals a sophisticated commercialization approach: developing platform technology that can be leveraged across multiple products ("develop once, deploy multiple times"). This creates a scalable revenue model beyond the initial
The partnership with Singapore's BICC adds strategic value through several concrete initiatives: establishing a joint laboratory, implementing technology exchange mechanisms, and integrating BICC's extensive Southeast Asian distribution network (3,000+ agents) with Shineco's domestic channels. This positions Shineco to expand beyond China into the lucrative Southeast Asian market.
The complementary nature of these announcements demonstrates management's execution of a cohesive strategy combining near-term revenue generation with long-term market expansion. The structured payment schedule tied to R&D milestones creates accountability while providing predictable cash flow. This approach addresses both immediate financial needs and long-term growth objectives through technology monetization and international market penetration.
As the core entity executing Shineco's strategy in the biocellular market, Dong'ao Health's new contract focuses on cutting-edge microalgae-derived extracellular vesicles technology. The service period runs from August 25, 2025, to December 31, 2026, with the goal of building a comprehensive, end-to-end R&D system from basic research to process development and product translation. Specific tasks include functional validation during the basic research phase; breaking bottlenecks in large-scale (e.g., hectoliter-scale) separation and extraction processes to achieve mass production; and developing at least two therapeutic products with full regulatory support to effectively transition the technology from the lab to the market.
This contract provides clear near-term financial momentum for Shineco. The total value of
"This contract is a powerful validation of our strategy to monetize cutting-edge research and create near-term revenue," said Jennifer Zhan, CEO of Shineco. "Coupled with our strategic alliance with BICC, it provides two clear, synergistic engines for growth that strengthen our domestic business while accelerating our international expansion."
Concurrent with this R&D progress, Shineco's international cooperation achieved a key milestone. BICC sent a high-level delegation to Dong'ao Health from September 6-10, including Chairman Mr. Yang Shengnan, CEO Ms. Barbara Tan, CFO Mr. Jon Lim, Chief Scientist Mr. Chen Yanming, and shareholder Mr. Chen Laifu.
The delegation conducted on-site inspections of Dong'ao Health's four core segments—the Health and Wellness Center, Cell R&D Center, under-construction Alzheimer's Disease Care Town, and partner "Anhe Meige Medical Aesthetic Hospital"—to evaluate potential synergies. The parties agreed to establish a joint laboratory, implement a technology exchange mechanism, integrate BICC's network of over 3,000 agents in
These dual developments exemplify Shineco's two-pronged strategy of "technology development plus ecosystem synergy." Technologically, the partnership combines complementary R&D capabilities and application scenarios. From a market perspective, the contracted revenue and BICC's international channels create a strategy of "a solid domestic base + expansion into new international markets." Financially, the deal improves short-term cash flow and enhances long-term profitability through technology leverage and market expansion.
"These advancements demonstrate the effective operation of our complete value chain from technology to industry to capital," CEO Jennifer Zhan emphasized. "Shineco remains committed to deepening our technology industrialization efforts and advancing international partnerships to deliver sustainable returns for our shareholders."
Shineco will provide regular updates on the contract's execution and the collaboration with BICC in accordance with NASDAQ disclosure rules.
About Xi'an Dong'ao Health Management Co., Ltd.
Xi'an Dong'ao Health provides GMP-compliant biostorage and clinical cell applications, delivering integrated health management via "Prevention-Intervention-Maintenance" protocols.
About BICC Pte Ltd
BICC Pte Ltd is a
About Shineco, Inc.
Shineco, Inc. is dedicated to improving quality of life through the development and provision of safe, efficient, and high-quality health and medical products and services. The Company's core business focuses on induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information, please visit www.biosisi.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco, Inc.
Email: secretary@shineco.tech
Phone: +86-10-68130220
View original content:https://www.prnewswire.com/news-releases/shineco-sisi-ignites-growth-8-7m-tech-deal--major-singapore-alliance-unleash-dual-engines-302554831.html
SOURCE Shineco,Inc.
FAQ
What is the value of Shineco's (SISI) new technology services contract?
What is the partnership between Shineco (SISI) and BICC?
How long is Shineco's (SISI) new technology development contract?
What are the main business segments of Shineco's (SISI) Dong'ao Health subsidiary?
How will the BICC partnership benefit Shineco (SISI)?
